Asthma Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID
| Verified date | October 2016 |
| Source | GlaxoSmithKline |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.
| Status | Completed |
| Enrollment | 600 |
| Est. completion date | July 2007 |
| Est. primary completion date | July 2007 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 15 Years and older |
| Eligibility |
Inclusion Criteria: - Have asthma for at least 3 months prior to the study. - Have been using an allowed pre-study asthma therapy for at least 3 months prior to study. - Currently have seasonal allergic rhinitis and have had seasonal onset of allergic rhinitis for at least the two previous allergy seasons. - Have a positive allergy skin test. Exclusion Criteria: - Have a history of life-threatening asthma. - Been hospitalized for asthma within the 6 months prior to the study. - Have certain conditions that would make study participation unsafe. The study doctor will evaluate other inclusion and exclusion criteria. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | GSK Investigational Site | Austin | Texas |
| United States | GSK Investigational Site | Austin | Texas |
| United States | GSK Investigational Site | Baltimore | Maryland |
| United States | GSK Investigational Site | Bethesda | Maryland |
| United States | GSK Investigational Site | Charleston | South Carolina |
| United States | GSK Investigational Site | Charleston | South Carolina |
| United States | GSK Investigational Site | Charlotte | North Carolina |
| United States | GSK Investigational Site | Charlottesville | Virginia |
| United States | GSK Investigational Site | Chattanooga | Tennessee |
| United States | GSK Investigational Site | Chevy Chase | Maryland |
| United States | GSK Investigational Site | Cincinnati | Ohio |
| United States | GSK Investigational Site | Collegeville | Pennsylvania |
| United States | GSK Investigational Site | Colorado Springs | Colorado |
| United States | GSK Investigational Site | Coral Gables | Florida |
| United States | GSK Investigational Site | Corsicana | Texas |
| United States | GSK Investigational Site | Covington | Louisiana |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Denver | Colorado |
| United States | GSK Investigational Site | Denver | Colorado |
| United States | GSK Investigational Site | East Providence | Rhode Island |
| United States | GSK Investigational Site | El Paso | Texas |
| United States | GSK Investigational Site | El Paso | Texas |
| United States | GSK Investigational Site | Eugene | Oregon |
| United States | GSK Investigational Site | Fountain Valley | California |
| United States | GSK Investigational Site | Germantown | Tennessee |
| United States | GSK Investigational Site | Gibsonia | Pennsylvania |
| United States | GSK Investigational Site | Greer | South Carolina |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Huntington Beach | California |
| United States | GSK Investigational Site | Iowa City | Iowa |
| United States | GSK Investigational Site | Ithaca | New York |
| United States | GSK Investigational Site | Kenilworth | Illinois |
| United States | GSK Investigational Site | Killeen | Texas |
| United States | GSK Investigational Site | Lafayette | Louisiana |
| United States | GSK Investigational Site | Lake Oswego | Oregon |
| United States | GSK Investigational Site | Lawrenceville | Georgia |
| United States | GSK Investigational Site | Lilburn | Georgia |
| United States | GSK Investigational Site | Little Rock | Arkansas |
| United States | GSK Investigational Site | Long Beach | California |
| United States | GSK Investigational Site | Los Angeles | California |
| United States | GSK Investigational Site | Marietta | Georgia |
| United States | GSK Investigational Site | Medford | Oregon |
| United States | GSK Investigational Site | Metairie | Louisiana |
| United States | GSK Investigational Site | Miami | Florida |
| United States | GSK Investigational Site | Murray | Utah |
| United States | GSK Investigational Site | North Andover | Massachusetts |
| United States | GSK Investigational Site | North Olmsted | Ohio |
| United States | GSK Investigational Site | Ocean | New Jersey |
| United States | GSK Investigational Site | Oklahoma City | Oklahoma |
| United States | GSK Investigational Site | Oklahoma City | Oklahoma |
| United States | GSK Investigational Site | Omaha | Nebraska |
| United States | GSK Investigational Site | Orange | California |
| United States | GSK Investigational Site | Ozark | Alabama |
| United States | GSK Investigational Site | Palmdale | California |
| United States | GSK Investigational Site | Philadelphia | Pennsylvania |
| United States | GSK Investigational Site | Philadelphia | Pennsylvania |
| United States | GSK Investigational Site | Plano | Texas |
| United States | GSK Investigational Site | Providence | Rhode Island |
| United States | GSK Investigational Site | Riverside | California |
| United States | GSK Investigational Site | Rolla | Missouri |
| United States | GSK Investigational Site | San Antonio | Texas |
| United States | GSK Investigational Site | San Antonio | Texas |
| United States | GSK Investigational Site | San Diego | California |
| United States | GSK Investigational Site | San Jose | California |
| United States | GSK Investigational Site | Sarasota | Florida |
| United States | GSK Investigational Site | Skillman | New Jersey |
| United States | GSK Investigational Site | South Burlington | Vermont |
| United States | GSK Investigational Site | Stockton | California |
| United States | GSK Investigational Site | Sylvania | Ohio |
| United States | GSK Investigational Site | Tampa | Florida |
| United States | GSK Investigational Site | Tempe | Arizona |
| United States | GSK Investigational Site | Vista | California |
| United States | GSK Investigational Site | Waco | Texas |
| United States | GSK Investigational Site | West Jordan | Utah |
| United States | GSK Investigational Site | Wheat Ridge | Colorado |
| United States | GSK Investigational Site | Winston-Salem | North Carolina |
| United States | GSK Investigational Site | Ypsilanti | Michigan |
| Lead Sponsor | Collaborator |
|---|---|
| GlaxoSmithKline |
United States,
This study has not been published in the scientific literature.
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Morning Peak Expiratory Flow | |||
| Secondary | Total Nasal Symptom Scores Morning Forced Expiratory Volume in 1 Second Asthma Symptom-Free Days Asthma Rescue-Free Days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|